azacitidina msn 25 mg/ml
pharmadox healthcare ltd. - malta - azacitidinum - pulb. pt. susp. inj. - 25 mg/ml - antimetaboliti analogi ai bazelor pirimidinice
azacitidina stada 25 mg/ml
pharmadox healthcare ltd. - malta - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice
vidaza
bristol-myers squibb pharma eeig - azacitidină - myelodysplastic syndromes; leukemia, myelomonocytic, chronic; leukemia, myeloid, acute - agenți antineoplazici - vidaza is indicated for the treatment of adult patients who are not eligible for haematopoietic stem cell transplantation (hsct) with: intermediate 2 and high-risk myelodysplastic syndromes (mds) according to the international prognostic scoring system (ipss),chronic myelomonocytic leukaemia (cmml) with 10 29 % marrow blasts without myeloproliferative disorder,acute myeloid leukaemia (aml) with 20 30 % blasts and multi-lineage dysplasia, according to world health organisation (who) classification. vidaza is indicated for the treatment of adult patients aged 65 years or older who are not eligible for hsct with aml with >30% marrow blasts according to the who classification.
onureg
bristol-myers squibb pharma eeig - azacitidină - leucemie, mieloidă, acută - agenți antineoplazici - onureg is indicated as maintenance therapy in adult patients with acute myeloid leukaemia (aml) who achieved complete remission (cr) or complete remission with incomplete blood count recovery (cri) following induction therapy with or without consolidation treatment and who are not candidates for, including those who choose not to proceed to, hematopoietic stem cell transplantation (hsct).
azacitidina onko 25 mg/ml
wessling hungary kft. - ungaria - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice
tibsovo
les laboratoires servier - ivosidenib - leukemia, myeloid, acute; cholangiocarcinoma - agenți antineoplazici - tibsovo in combination with azacitidine is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) with an isocitrate dehydrogenase-1 (idh1) r132 mutation who are not eligible to receive standard induction chemotherapy (see section 5. tibsovo monotherapy is indicated for the treatment of adult patients with locally advanced or metastatic cholangiocarcinoma with an idh1 r132 mutation who were previously treated by at least one prior line of systemic therapy.
venclyxto
abbvie deutschland gmbh co. kg - venetoclax - leucemie, limfocitică, cronică, celule b - agenți antineoplazici - venclyxto in combination with obinutuzumab is indicated for the treatment of adult patients with previously untreated chronic lymphocytic leukaemia (cll) (see section 5. venclyxto in combination with rituximab is indicated for the treatment of adult patients with cll who have received at least one prior therapy. venclyxto monotherapy is indicated for the treatment of cll:- in the presence of 17p deletion or tp53 mutation in adult patients who are unsuitable for or have failed a b cell receptor pathway inhibitor, or- in the absence of 17p deletion or tp53 mutation in adult patients who have failed both chemoimmunotherapy and a b-cell receptor pathway inhibitor. venclyxto in combination with a hypomethylating agent is indicated for the treatment of adult patients with newly diagnosed acute myeloid leukaemia (aml) who are ineligible for intensive chemotherapy.
vidaculem 25 mg/ml
seacross pharma (europe) limited - irlanda - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice
laziros 25 mg/ml
stada arzneimiitel ag - germania - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice
zassida 25 mg/ml
aqvida gmbh - germania - azacitidinum - pulb. pt. susp. inj. - 25mg/ml - antimetaboliti analogi ai bazelor pirimidinice